New Oral Drug for Huntington's Aims to Halt Disease at Genetic Source

WOBURN, MA – February 25, 2026 – In a significant development for the Huntington's disease community, Rgenta Therapeutics has unveiled promising preclinical data for a novel, orally administered drug candidate that targets the genetic instability at the very root of the devastating neurodegenerative disorder. The data, presented this week at the 21st Annual Huntington’s Disease (HD) Therapeutics Conference in Palm Springs, CA, introduces RGT-0474060 as a potential first-in-class therapy designed not just to manage symptoms, but to halt the disease's underlying progression.

For the estimated 41,000 Americans living with Huntington's disease and the 200,000 more who carry the gene, the announcement represents a potential turning point. HD is an inherited, progressive disorder that relentlessly breaks down nerve cells in the brain, leading to uncontrollable movements (chorea), cognitive decline, and severe psychiatric problems. Until now, available treatments have been limited to alleviating symptoms, leaving the disease's destructive course unchecked.

Rgenta’s candidate, however, employs a fundamentally different strategy. The company is now advancing RGT-0474060 into the necessary studies required to file an Investigational New Drug (IND) application with regulators, setting a goal to initiate human clinical trials in 2027.

A Novel Attack on Genetic Instability

Huntington's disease is caused by an abnormal expansion of a DNA sequence, known as a CAG repeat, within the huntingtin (HTT) gene. This mutation produces a toxic protein (mHTT) that kills neurons. A key discovery in recent years is that this genetic stutter doesn't just exist from birth; it worsens over time within a patient's own cells, particularly in the brain. This process, called somatic CAG-repeat expansion, is a major driver of disease onset and severity.

RGT-0474060 is engineered to stop this expansion. It works by inhibiting a gene called PMS1, which has been identified as a critical driver of the somatic expansion process. By reducing PMS1 levels, the drug effectively puts the brakes on the accumulating genetic damage.

“Targeting somatic CAG repeat expansion in the HTT gene, the mutation that causes HD, through a reduction of PMS1 is a promising strategy for treating HD and potentially transformative in our care of patients with this devastating disease,” said Sarah Tabrizi, M.D., Ph.D., a professor of Clinical Neurology at University College London and a leading HD researcher.

Dr. Tabrizi, who was quoted in the company's press release, emphasized the profound unmet need. “For our Huntington’s disease patients there are no disease modifying therapies yet available... With future therapies, like RGT-0474060, we hope to have treatments that have the potential to slow, and possibly halt, disease progression.”

This mechanism marks a significant departure from many other therapeutic strategies in development, which largely focus on reducing the levels of the toxic mHTT protein after it has been produced from the faulty gene.

Unpacking the Preclinical Promise

The data presented by Rgenta highlighted several crucial attributes that make RGT-0474060 a compelling candidate. In preclinical models of Huntington's, the drug demonstrated robust efficacy, a well-tolerated safety profile, and superior selectivity.

Critically, RGT-0474060 is an oral, small molecule that can cross the blood-brain barrier. This is a massive potential advantage. It means the drug can be taken as a simple pill and can effectively reach the nerve cells in the brain where it is needed most. This stands in stark contrast to other advanced therapeutic approaches for HD that require invasive procedures, such as intrathecal injections into the spinal fluid or direct neurosurgery to deliver gene therapies.

According to the presentation, the drug achieved a dose-dependent reduction of PMS1 in brain tissues, which directly correlated with the suppression of CAG-repeat expansion. This on-target activity in a brain-penetrant molecule validates the scientific hypothesis and underscores its potential as a disease-modifying agent.

“The mechanism of RGT-0474060 is a direct, on-target hit to the underlying cause of HD and a testament to the power of our RNA-targeting small molecule discovery platform,” stated Travis Wager, Ph.D., co-founder and chief scientific officer of Rgenta. He noted the drug's emerging profile supports “favorable safety, pharmacokinetics, and pharmacodynamic properties that make it an ideal drug candidate.”

Navigating a Challenging Landscape

Rgenta's promising candidate enters a field marked by both intense hope and significant setbacks. The pipeline for HD therapies is more robust than ever, but the path to approval is fraught with challenges.

Several high-profile programs have faced hurdles. Roche's tominersen, an antisense oligonucleotide (ASO) designed to lower huntingtin protein, had its Phase 3 trial halted in 2021 before being re-initiated in a more targeted patient population. More recently, uniQure's one-time gene therapy, AMT-130, delivered promising early data but faced a setback in late 2025 when the FDA indicated the results were not yet sufficient to support a regulatory filing, casting uncertainty on its path forward despite multiple expedited review designations.

These experiences highlight the immense difficulty of treating neurodegenerative diseases and the high bar set by regulators. However, they also underscore the unique position of RGT-0474060. Its status as an oral small molecule could offer a more accessible and less invasive alternative to the ASOs and gene therapies being developed by competitors like Wave Life Sciences, PTC Therapeutics, and Alnylam Pharmaceuticals.

The Road to the Clinic

Founded just six years ago, Rgenta has rapidly built a pipeline based on its proprietary platform, which designs small molecules to modulate RNA and regulate gene expression. This technology has already produced a clinical-stage candidate for oncology, RGT-61159, which is in Phase 1 trials for several types of cancer. The company's progress is backed by significant venture funding and strategic research collaborations with major pharmaceutical players, including GSK and Lundbeck.

This strong foundation provides the resources and expertise needed for the long and expensive journey ahead for RGT-0474060. The next step involves comprehensive IND-enabling studies, which are designed to ensure the drug is safe enough to be tested in humans. If successful, Rgenta plans to begin Phase 1 clinical trials in 2027.

For a community that has waited decades for a therapy that can alter the course of their disease, the journey from a promising preclinical result to an approved medicine remains long. Yet, the emergence of an oral drug candidate that targets the genetic engine of Huntington's disease represents a tangible and powerful new source of optimism.